Riccardo De Giorgi (@rdegiorgi) 's Twitter Profile
Riccardo De Giorgi

@rdegiorgi

MD, DPhil, MRCPsych. Clinical Lecturer ST4-6 at University of Oxford, Department of Psychiatry

ID: 474114123

linkhttps://www.psych.ox.ac.uk/team/riccardo-de-giorgi calendar_today25-01-2012 17:25:44

414 Tweet

283 Followers

386 Following

Riccardo De Giorgi (@rdegiorgi) 's Twitter Profile Photo

📣 Read our new meta-analysis on JAMA Psychiatry jamanetwork.com/journals/jamap… investigating #GLP1RAs and mental health outcomes in people with T2DM and obesity - an important study led by Aureliane Pierret & Toby Pillinger

📣 Read our new meta-analysis on <a href="/JAMAPsych/">JAMA Psychiatry</a> jamanetwork.com/journals/jamap… investigating #GLP1RAs and mental health outcomes in people with T2DM and obesity - an important study led by Aureliane Pierret &amp; <a href="/tobypill/">Toby Pillinger</a>
JAMA Psychiatry (@jamapsych) 's Twitter Profile Photo

GLP1-RA treatment for obesity and diabetes does not increase psychiatric adverse events compared to placebo and is linked to improvements in quality of life, emotional eating, and mental well-being. ja.ma/4khzu1z Riccardo De Giorgi KCLDiabetesPsych

Nature Mental Health (@natmenthealth) 's Twitter Profile Photo

🔙 #tbt #MentalHealthAwarenessMonth 🚨Riccardo De Giorgi et al. from the University of Oxford present a thorough analysis of pre-clinical and clinical studies examining the role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in #mental disorders. nature.com/articles/s4422…

JAMA Psychiatry (@jamapsych) 's Twitter Profile Photo

Most viewed this week from JAMA Psychiatry: GLP1-RA treatment for obesity and diabetes does not increase psychiatric adverse events compared to placebo and is linked to improvements in quality of life, emotional eating, and mental well-being. ja.ma/4kqyZ5r

Most viewed this week from <a href="/JAMAPsych/">JAMA Psychiatry</a>:

GLP1-RA treatment for obesity and diabetes does not increase psychiatric adverse events compared to placebo and is linked to improvements in quality of life, emotional eating, and mental well-being.

ja.ma/4kqyZ5r
JAMA Psychiatry (@jamapsych) 's Twitter Profile Photo

Most viewed this week from JAMA Psychiatry: GLP1-RA treatment for obesity and diabetes does not increase psychiatric adverse events compared to placebo and is linked to improvements in quality of life, emotional eating, and mental well-being. ja.ma/43owISN

Most viewed this week from <a href="/JAMAPsych/">JAMA Psychiatry</a>: 

GLP1-RA treatment for obesity and diabetes does not increase psychiatric adverse events compared to placebo and is linked to improvements in quality of life, emotional eating, and mental well-being. 

ja.ma/43owISN
JAMA Psychiatry (@jamapsych) 's Twitter Profile Photo

Most viewed this week from JAMA Psychiatry: GLP1-RA treatment for obesity and diabetes does not increase psychiatric adverse events compared to placebo and is linked to improvements in quality of life, emotional eating, and mental well-being. ja.ma/44Voqmu

Most viewed this week from <a href="/JAMAPsych/">JAMA Psychiatry</a>: 

GLP1-RA treatment for obesity and diabetes does not increase psychiatric adverse events compared to placebo and is linked to improvements in quality of life, emotional eating, and mental well-being. 

ja.ma/44Voqmu
JAMA Psychiatry (@jamapsych) 's Twitter Profile Photo

Simvastatin added to escitalopram did not improve depressive symptoms in patients with major depressive disorder and obesity, although it reduced cholesterol and C-reactive protein levels. ja.ma/43Hi33P

Simvastatin added to escitalopram did not improve depressive symptoms in patients with major depressive disorder and obesity, although it reduced cholesterol and C-reactive protein levels. ja.ma/43Hi33P